Genmab's Virtual Capital Markets Day
NOVEMBER 13, 2020
On Friday, November 13, 2020, Genmab hosted a virtual Capital Markets Day (CMD) for investors and analysts.
The event was webcast live from Genmab’s state-of-the-art R&D Center in Utrecht, the Netherlands, and from its new offices and laboratory facilities in Princeton, NJ, US. The CMD featured Genmab’s Executive Management Team and a variety of Genmab speakers. The Team provided updates on Genmab’s business, the ways in which we are delivering on our promise, and how we are evolving into a fully integrated biotech.
Topics discussed included an overview of our robust pipeline with a focus on our exciting epcoritamab, tisotumab vedotin and DuoBody®-PD-L1x4-1BB programs, a deep dive into our proprietary DuoBody® technology, and a look at how we are growing our capabilities across the company.
The full broadcast is featured below, for your viewing. If you would like to download or view any of the individual presentations, you can do so by navigating to the Agenda page, and clicking on the individual session(s).
Jan van de Winkel
President & Chief Executive Officer
Executive Vice President & Chief Development Officer
Executive Vice President & Chief Financial Officer
EVP & Chief Operating Officer
Senior Vice President, Head of Oncology
Corporate Vice President, Translational Research
Vice President, New Antibody Products
Rob de Jong
Director Antibody Research & Technology